• Everyone is friendly and very informative.

    They explain all procedures and why. The staff is courteous and friendly and they listen. They ask often if you need anything, are friendly and smiling. A smile always goes a long way, even when you don’t feel like smiling.

    -Diane, Study Participant
  • I am never anxious on visits; 

    very helpful staff.

    -Donald, Study Participant
  • Wonderful!

    Everyone is so friendly each time I have an appointment.

    -Gloria, Study Participant
  • Awesome!

    -GSK Monitor
  • It is a pleasure working with such a dedicated research team 

    and I would definitely like to collaborate with your site on future trials. I sincerely appreciate all of the efforts made to date on our studies!

    -GSK Monitor
  • Well executed, punctual. 

    Good job, keep up the good work.

    -Joel, Study Participant
  • Thanks for the important work you are doing. 

    ALL of you are great.

    -Jolene, Study Participant
  • Laura R, Dr. Holcomb and the rest of the staff are super professionals! 

    Happy to be part of this study; will recommend this clinic to others!

    -Lou, Study Participant
  • The staff is upbeat, friendly and positive. 

    Very willing to make the testing sessions as comfortable as if one is at home. The staff treats me with care, compassion and understanding.

    -Mary Ann, Study Participant
  • Educational, pleasant, concerned with my health, 

    as well as the study performance. A combination of professional and a concerned family.

    -Michael, Study Participant
  • The staff is extremely welcoming and supportive

    Everyone is aware of their responsibilities, knowledgeable of research and very cooperative. The entire organization is well run from the top down. This is my favorite site to work with!

    -Novum Monitor
  • Study Coordinators were very responsive to my emails 

    and requests for study questions. Staff at the site is very friendly and accommodating. Patients' charts are very well organized and complete

    -Quintiles Monitor
  • Very pleasant and friendly staff.

    They are very considerate to make every effort to make me comfortable.

    -Ralph, Study Participant
  • This site does quality work 

    and pays attention to detail. Data corrections are usually handled quickly. All staff seem organized and are conscientious about their work.

    -Sanofi Monitor
  • Lisa Lopez and the entire staff are extremely professional, courteous, welcoming, etc. 

    I never felt I was in a doctor’s office; it felt like being at home.

    -Sara, Study Participant
  • The staff was friendly and knowledgeable. 

    Principal Investigator was available to meet and showed oversight in source. Data and regulatory binders were clean and well maintained.

    -Wyeth Monitor

Director of Clinical Research

CHARLES P. ANDREWS, MD, CPI

DIAGNOSTICS RESEARCH GROUP

4410 Medical Drive, Suites 360 and 320

San Antonio, Texas 78229

Phone (210) 692-7157

Fax  (210) 692-1999


EDUCATION & TRAINING

1971    The University of Texas at Austin; B.A. 

1975  The University of Texas Southwestern Medical School, Dallas; M.D. (Medical School)

1975 -1976  Bexar County Hospital and Audie L. Murphy Memorial Veterans Hospital, San Antonio,

Texas (Internal Medicine Internship)

1976 -1978  Bexar County Hospital and Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas (Internal Medicine Residency)

1978 -1980  The University of Texas Health Science Center, San Antonio, Texas (Pulmonary Disease Fellowship)


CURRENT POSITIONS

1982 - present  Pulmonary Physician in private practice, San Antonio, Texas

2000 - present  Director of Clinical Research - Diagnostics Research Group, San Antonio, Texas

2009 - present  Shareholder and Principal Investigator, Biogenics Research Chamber

2010 - present  Director of Pulmonary Dynamics

2013-  present  Contract Investigator, ICON Development Solutions


CERTIFICATION & LICENSURE

Licensure

1975  MD - Texas

Certification

1978  American Board of Internal Medicine

1980  Subspecialty Board of Pulmonary Disease

2002  Clinical Investigator Certification, Association of Clinical Research Professionals

2014  Recertification, Association of Clinical Research Professionals


PROFESSIONAL APPOINTMENTS

1981-1982  Assistant Professor of Medicine, The University of Texas Health Science Center at San Antonio, Texas

1980-1981  Medical Director, Medical Intensive Care Unit, Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas

1982-present  Clinical Associate Professor of Medicine, University of Texas Health Science Center, San Antonio, Texas

1982-present  Staff Physician, Southwest Texas Methodist Hospital, San Antonio, Texas

1982-2012  Staff Physician, St. Luke’s Lutheran Hospital, San Antonio, Texas

1982-present  Staff Physician-Methodist Specialty and Transplant Hospital, San Antonio, Texas

1985-1998  Staff Physician, Humana Women’s Hospital, San Antonio, Texas

1986-2013  Staff Physician, St. Rose Hospital, San Antonio, Texas

1999-2013  Staff Physician, Memorial Hospital, Gonzales, Texas

2000-2012  Staff Physician, Uvalde Memorial Hospital, San Antonio, Texas

2000-present  Staff Physician, Life Care Hospital, San Antonio, Texas

2004- present  Staff Physician, Texan Hospital, San Antonio, Texas


HONORS

1970  Phi Beta Kappa (Undergraduate)

1971  Aesculapius Award for Highest Grade Point Average of a pre-medical student at The University of Texas, Austin

1999  Listed in Who’s Who

2001  Texas Organ Sharing Alliance Award for Healthcare Professionals

2003  Private Practice Leadership Development, American College of Chest Physicians

2005  Listed in Consumer’s guide to Top Doctors

Finalist Cecile Lehman Mayor Research Forum, American College of Chest Physicians

Fellow American College of Chest Physicians

Fellow American College of Physicians

Texas Best Doctors and San Antonio Best Doctors Awards


PROFESSIONAL ORGANIZATIONS

American Academy of Allergy, Asthma and Immunology

American College of Asthma, Allergy and Immunology, Scientific Fellow

American College of Chest Physicians, Fellow and member of the Clinical Research Steering Committee of Chest

American College of Physicians, Fellow

American Thoracic Society

Association of Clinical Research Professionals

Bexar County Medical Society

Drug Information Association

Texas Medical Association

American Academy of Pharmaceutical Physicians

The Association for Research in Vision and Ophthalmology

European Academy of Allergy and Clinical Immunology


COMMUNITY SERVICE

President, South Texas Organ Bank 1993-1998; Currently Board Member and member of the Executive Committee

Co-chair for Fund Raising for Nurses’ House for Habitat for Humanity 1994

Board Member, Alumni Association, University of Texas Southwestern Medical School, Dallas, Texas 2004-2006

Judge for Health Sciences, San Antonio Regional Science Fair 2005

Board of Trustees, Keystone School, San Antonio, Texas 2009 – 2015, Vice-President 2012- 2015


PREVIOUS POSITIONS & COMMITTEE MEMBERSHIPS

Medical Director Intensive Care Unit, Southwest Texas Methodist Hospital

Chairman Section of Diseases of the Chest, Texas Medical Association

Chairman of Pulmonary Department, Methodist Specialty and Transplant Hospital

Member of the Executive Committee, Southwest Texas Methodist Hospital

Member of the Search Committee for Medicine Department Chairman, University of Texas Health Science Center, San Antonio, Texas 1978

Medical Director, Intensive Care Unit, Rehabilitation Institute of San Antonio, Texas 1988-1995

Medical Director, Pulmonary Care, Rehabilitation Institute of San Antonio, Texas 1988-2000

President of Medical Staff, Rehabilitation Institute of San Antonio, Texas 2000

President of Pulmonary Physicians, P.A. 2007-2012.


CLINICAL RESEARCH

Comparative Antibiotic Study in the Treatment of Acute Exacerbation of Chronic Bronchitis. Phase III. 1999. Principal Investigator

Inpatient Antibiotic Study of the Treatment of Hospital Acquired Pneumonia.

Phase III. 1999. Principal Investigator

Asthma. Phase II. 2000. Principal Investigator

Asthma/Chronic Obstructive Pulmonary Disease: A Non-Comparative Study to Assess XXXX in Patients with Bronchospasm. Phase IV. 2000. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2000. Principal Investigator

Asthma. Bronchodilator. Phase IV. 2000. Principal Investigator

Inpatient Antibiotic Study of the Treatment of Community-Acquired Pneumonia.

Phase IV. 2000. Principal Investigator

Chronic Obstructive Pulmonary Disease-Anti-inflammatory. Phase III. 2001. Principal Investigator

Acute Exacerbation of Chronic Bronchitis. Phase III. 2001. Principal Investigator

Inpatient Antibiotic Study of the Treatment of Community-Acquired Pneumonia.

Phase III. 2001. Principal Investigator

Acute Bacterial Exacerbation of Chronic Bronchitis. Phase III. 2002. Sub-Investigator

Seasonal Allergic Rhinitis. Phase III. 2001. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2001. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IV. 2002. Principal Investigator

Asthma. Phase III. 2002. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2001. Principal Investigator

Seasonal Allergic Rhinitis and Concomitant Asthma. Phase II. 2001. Principal Investigator

Diagnosis of Lung Cancer by Sputum Cytology. Phase II. 2002. Principal Investigator

Severe Sepsis. Inpatient. Phase II. 2002. Sub-Investigator

Asthma. Phase III. 2002. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IV. 2002. Principal Investigator

Asthma. Phase III. 2002. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2002 Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2002. Principal Investigator

Acute Exacerbation of Chronic Bronchitis Phase III. 2002. Principal Investigator

Asthma. Phase III. 2002. Principal Investigator

Perennial Allergic Rhinitis. Phase IIIa. 2002. Principal Investigator

Seasonal Allergic Rhinitis and Concomitant Asthma. Phase IV. 2002. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2003. Principal Investigator

Asthma. Phase III. 2003. Sub-Investigator

Asthma. Phase III. 2003. Principal Investigator

Seasonal Allergic Rhinitis and Concomitant Asthma. Phase III. 2003. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2003. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2003. Principal Investigator

Seasonal Allergic Rhinitis. Phase II. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2003. Principal Investigator

Inpatient Antibiotic Study of the Treatment of Community Acquired Pneumonia. Phase IV. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2003. Principal Investigator

Perennial Allergic Rhinitis. Phase III. 2003. Principal Investigator

Perennial Allergic Rhinitis. Phase III. 2003. Principal Investigator

Vulvovaginal Candidiasis. Phase IV. 2003. Sub-Investigator

Hypertension. Phase III. 2003. Principal Investigator

Asthma. Phase III. 2003. Principal Investigator

Asthma. Phase III. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2003. Sub-Investigator

Chronic Obstructive Pulmonary Disease/Asthma Inpatient Study. Phase IV. 2003. Principal Investigator

Inpatient antibiotic study of the treatment of Community-Acquired Pneumonia. Phase III. 2003. Principal Investigator

Asthma. Phase IV. 2003. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2003. Principal Investigator

Seasonal Allergic Rhinitis and Concomitant Asthma. Phase IV. 2004. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2004. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2004. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2004. Principal Investigator

Inpatient Bronchoscopy Sedation. Phase III. 2004. Principal Investigator

Asthma. Phase IIa. 2004. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2004. Sub-Investigator

Asthma. Phase III. 2004. Principal Investigator

Stress Urinary Incontinence. Phase IV. 2004. Principal Investigator

Osteoporosis. Phase IIIb. 2004. Principal Investigator

Parkinson’s Disease. Phase IIIb. 2004. Sub-Investigator.

Uncomplicated Hypertension. Phase III. 2004. Principal Investigator

Inpatient Complicated Urinary Tract Infection. Phase IIb. 2004. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2004. Sub-Investigator

Female Dyspepsia. Phase III. 2004. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2004. Sub-Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2004. Principal Investigator

Asthma. Phase III. 2005. Principal Investigator

Seasonal Allergic Rhinitis. Phase II. 2005. Principal Investigator

Asthma. Phase II. 2005. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2005.Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2005. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2005. Principal Investigator

Asthma/Allergy. Phase IV. 2005. Principal Investigator

Chronic Obstructive Pulmonary Disease/Asthma. Phase IIIb. 2005. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2005. Principal Investigator

Osteoporosis. Phase IIIb. 2005. Principal Investigator

Diabetes. Phase II. 2005. Principal Investigator

Cardiovascular Event Prevention. Phase III. 2005. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2005. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIb. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IV. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Observational. 2006. Principal Investigator

Acute Exacerbation Chronic Obstructive Pulmonary Disease. Phase IV. 2006. Principal Investigator

Acute Exacerbation of Chronic Bronchitis/Chronic Obstructive Pulmonary Disease. Phase II. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Questionnaire. 2006. Principal Investigator

Pulmonary Arterial Hypertension / Chronic Obstructive Pulmonary Disease. Phase IIa. 2006. Sub-Investigator

Diabetes. Phase III. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2006. Principal Investigator

Dyspepsia. Phase II. 2006. Principal Investigator

Dyslipidemia. Phase III. 2006. Principal Investigator

Dyslipidemia. Phase III. 2006. Principal Investigator

Abdominal Pain. Phase II. 2006. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2006. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2006. Sub-Investigator

Diabetes. Phase III. 2006. Principal Investigator

Dyslipidemia. Phase III. 2006. Principal Investigator

Pulmonary Arterial Hypertension. Phase IV. 2006. Sub-Investigator

Hyperlipidemia. Phase III. 2006. Principal Investigator

Perennial Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2006. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2007. Principal Investigator

Asthma. Phase IIb. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2007. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2007. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIb. 2007. Principal Investigator

Asthma. Phase III. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2007. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase II. 2007. Principal Investigator

Osteoarthritis of the Knee. Phase II. 2007. Principal Investigator

Irritable Bowel Syndrome. Phase III. 2007. Principal Investigator

Irritable Bowel Syndrome. Phase III. 2007. Principal Investigator

Hypertension. Phase III. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase IIb. 2007. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II/III. 2007. Principal Investigator

Osteoarthritis. Phase III. 2007. Principal Investigator

Herpes Zoster Vaccine. Phase IV. 2007. Principal Investigator

Idiopathic Pulmonary Fibrosis. Phase III. 2007. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIb. 2007. Principal Investigator

Asthma. Phase IV. 2007. Principal Investigator

Osteoarthritis. Phase III. 2007. Principal Investigator

Seasonal Allergic Rhinitis. Phase II. 2008. Principal Investigator

Seasonal Allergic Rhinitis. Questionnaire. 2008. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2008. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2008. Principal investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2008. Principal Investigator

Pulmonary Arterial Hypertension. Device. 2008. Sub-Investigator

Seasonal Allergic Rhinitis. Phase III. 2008. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIExtension. 2008. Principal Investigator

Asthma. Phase IV. 2008. Principal Investigator

Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator

Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator

Pneumonia Vaccine. Phase III. 2008. Principal Investigator

Pneumonia Vaccine, Phase III. 2008. Principal Investigator

Hypercholesterolemia. Phase III. 2008. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIb. 2008. Principal Investigator

Osteoarthritis of the Knee. Phase II. 2008. Principal Investigator

Chronic Constipation. Phase III. 2008. Principal Investigator

Asthma. Phase II. 2008. Principal Investigator

Asthma. Phase II. 2008. Principal Investigator.

Chronic Constipation/Irritable Bowel Syndrome Safety. Phase III. 2008. Principal Investigator

Hypertension. Phase IV. 2008. Principal Investigator

Hypertension/Diabetes. Phase IV. 2008. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2008. Sub-Investigator

Pulmonary Arterial Hypertension. Phase III. 2008. Sub-Investigator

Osteoarthritis of the Knee. Phase III. 2008. Principal Investigator

Osteoarthritis of the Hip. Phase III. 2008. Principal Investigator

Osteoarthritis of the Knee. Phase III. 2008. Principal Investigator

Idiopathic Pulmonary Fibrosis. Phase IIIb. Extension study 2008. Principal Investigator

Perennial Allergic Rhinitis. Phase IV. 2008. Principal Investigator

Hypercholesterolemia.  Phase III. 2009. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2009. Sub-Investigator

Abdominal Pain. Phase II. 2009. Principal Investigator

Chronic Constipation/Irritable Bowel Syndrome. Phase III. 2009. Sub-Investigator

Pulmonary Arterial Hypertension. Phase III. 2009. Sub-Investigator

Osteoarthritis of the Knee/Hip. Phase III. Extension Study. Principal Investigator

Hypertension. Phase III. 2009. Sub-Investigator

Abdominal Pain. Phase II. 2009. Principal Investigator

Osteoarthritis of Knee. Phase III. 2009. Principal Investigator

Chronic Constipation / Irritable Bowel Syndrome. Phase III. 2009. Sub-Investigator

Chronic Obstructive Pulmonary Disease. Phase IIa. 2009. Sub-Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2009. Sub-Investigator

Chronic Obstructive Pulmonary Disease. Phase III. Extension Study. Sub-Investigator

Asthma. Phase II. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIa. 2009. Sub-Investigator

Seasonal Allergic Rhinitis. Phase II/III. 2009. Principal Investigator

Pulmonary Arterial Hypertension. Phase III. 2009. Principal Investigator

Rota Virus Vaccine. Phase I. 2009. Principal Investigator

Influenza Vaccine. Phase IV. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2009. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2009. Principal Investigator

Perennial Allergic Rhinitis. Phase III. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2009. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2009. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2009. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2009. Principal Investigator

Hypertension. Phase IIIb. 2010. Sub-Investigator

Diarrhea / Irritable Bowel Syndrome. Phase II. 2010. Principal Investigator

Hypercholesterolemia. Phase III. 2010. Principal Investigator

Primary Insomnia. Phase III. 2010. Sub-Investigator

Herpes Zoster Vaccine. Phase III. 2010. Principal Investigator

Herpes Zoster Vaccine. Phase III. 2010. Principal Investigator

Asthma. Phase III. 2010. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2010. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2010. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2010. Sub-Investigator

Seasonal Allergic Rhinitis. Phase II. 2010. Principal Investigator 

Asthma. Phase III. 2010. Principle Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2010. Principle Investigator

Asthma. Phase IIa. 2010. Principle Investigator 

Chronic Obstructive Pulmonary Disease. Phase III. 2010. Principle Investigator

Seasonal Allergic Rhinitis. Phase III. 2010. Principal Investigator

Idiopathic Pulmonary Fibrosis. Phase IIIb. 2010. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase II. 2010. Sub-Investigator

Asthma. Phase IIb. 2010. Principal Investigator

Seasonal Allergic Rhinitis. Phase III. 2010.  Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIb. 2010. Sub-Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIa. 2011. Principal Investigator

Hypercholesterolemia. Phase III. 2011. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIa. 2011. Principal Investigator

Idiopathic Pulmonary Fibrosis. Phase III. 2011. Principal Investigator

Hypercholesterolemia. Phase III. 2011. Principal Investigator

Environmental Chamber. Phase II. 2011. Principal Investigator

Environmental Chamber. Phase IV. 2011. Sub-Investigator

Seasonal Allergy Rhinitis. Phase III. 2011. Principal Investigator

Seasonal Allergy Rhinitis. Phase III. 2011. Principal Investigator

Seasonal Allergy Rhinitis. Phase III. 2011. Principal Investigator

Influenza Vaccine. Phase IIIb/IV.2011.  Principal Investigator

Hypertension. Phase III.2012. Principal Investigator.

Pneumonia Vaccine. Phase IIb.2012. Principal Investigator.

Asthma. Phase IIb.2012. Principal Investigator.

Chronic Obstructive Pulmonary Disease. Phase III.2012. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III.2012. Principal Investigator.

Perennial Allergic Rhinitis. Phase I.2012. Principal Investigator

Constipation. Phase IIIb.2012. Sub-Investigator

Irritable Bowel Syndrome.Phase III.2012. Principal Investigator

Hypertension. Phase II.2012. Sub-Investigator

Environmental Chamber. Phase I.2012.Sub Investigator

Seasonal Allergic Rhinitis. Bio.2012.Principal Investigator

Environmental Chamber.Phase I. 2012. Principal Investigator

Perennial Allergic Rhinitis. Phase III. 2013. Principal Investigator

Seasonal Allergic Rhinitis. Bio.2013. Principal Investigator

Chronic Cough. Phase II. 2013. Sub Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2013. Sub Investigator

Osteoarthritis. Phase III. 2013. Principal Investigator

Osteoarthritis. Phase III. 2013. Principal Investigator

Seasonal Allergic Rhinitis. Phase IV. 2013. Principal Investigator

Seasonal Allergic Rhinitis. Bio. 2013. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2013. Sub Investigator

Chronic Obstructive Pulmonary Disease. (Diary Validation). 2013. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2013. Principal Investigator

Seasonal Allergic Rhinitis. Bio. 2014. Principal Investigator

Seasonal Allergic Rhinitis. Phase II. 2014. Principal Investigator

Hypertension. Phase II. 2014. Sub Investigator

Chronic Obstructive Pulmonary Disease. Phase IIIb. 2014. Principal Investigator

Chronic Obstructive Pulmonary Disease. Phase III. 2014. Principal Investigator

COPD. Phase II. 2014. Sub Investigator

COPD. Phase II. 2014. Sub Investigator

Osteoarthritis. Open Label. 2014. Principal Investigator

Seasonal Allergic Rhinitis. Bio. 2014. Principal Investigator

Environmental Chamber. Phase II. 2014. Principal Investigator

COPD. Phase IIIb. 2014. Principal Investigator

Seasonal Allergic Rhinitis. Bio. 2014. Principal Investigator

Seasonal Allergic Rhinitis. Bio. 2014. Principal Investigator

COPD. Phase IIIb. 2014. Principal Investigator

Herpes Zoster Vaccine. Phase III. 2015. Principal Investigator

Herpes Zoster Vaccine. Phase III. 2015. Principal Investigator

Pneumonia Vaccine. Phase III. 2015. Principal Investigator

IBS with Constipation. Phase III. 2015. Sub Investigator

COPD. Phase III. 2015. Principal Investigator

COPD. Phase IIa. 2015. Sub Investigator

Pneumonia Vaccine. Phase II. 2015. Principal Investigator

Bibliography

Andrews CP, Smith JD, Johanson Jr. WG. Pulmonary effects of methylmethacrylate vapor exposure in dental students.  Clin Res. 1979;(Abstr.) 27:759A.

 Andrews CP, Shaw JO. In vitro functional capacity of bronchoalveolar neutrophils.  Am Rev Respir Dis. 1980;121:54.

Andrews CP, Weiner MH. Diagnosis of invasive pulmonary aspergillosis: fungal antigen detected by radioimmunoassay in bronchoalveolar lavage fluid.  Chest 1980; (Abstr.) 78:507. Presented at the Cecile Lehman Mayer Research Forum of the 46th Annual Scientific Assembly of the American College of Chest Physicians, October 29, 1980.

Shaw JO, Kolb WP, Andrews CP, Fine R, Johanson Jr. WG. C5-derived chemotactic peptides and neutrophils in the alveolus as potential pathogenic factors in interstitial fibrosis. Presented at the International Colloquium on Pulmonary Fibrosis, London, England, February 1980.

Shaw JO, Wetsel RA, Andrews CP, Kolb WP.  C5 cleaving enzyme(s) in the airspaces of patients with acute respiratory distress syndrome.  Clin Res. 1980; (Abstr.)28:842A.

Andrews CP, Coalson JJ, Smith JD, Johanson Jr. WG. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury (ARDS).  Presented to Third World Congress on Intensive and Critical Care Medicine, May 1981.  Crit Care Med. 1981;(Abstr.)9:197.

Andrews CP, Coalson JJ, Smith JD, Johanson Jr. WG. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury (ARDS). Chest. 1981;80:254-258.

Andrews CP, Weiner MH. Immunodiagnosis of invasive pulmonary aspergillosis: Fungal antigen detected by radioimmunoassay in bronchoalveolar lavage fluid. Am Rev Resp Dis. 1981;124:60-64.

Shaw JO, Ferrigni KS, Wetsel RA, Andrews CP, Kolb WP. C5 cleaving enzyme(s) in the airspaces of patients with acute respiratory distress syndrome.  Am Rev Respir Dis. 1981;(Abstr.)123:51.

Andrews CP, Weiner MH. Effects of bronchoalveolar lavage fluid concentration on radioimmunoassay detection of Aspergillus antigen in experimental and human infection.  Am Rev Respir Dis. 1981;(Abstr.)123:260.

Andrews CP, Weiner MH. Radioimmunoassay detection of aspergillus carbohydrate in sequential bronchoalveolar lavages during pulmonary aspergillosis.  Chest. 1981;(Abstr.)80:341-342.

Andrews CP, Drutz DJ, Coalson JJ, Johanson Jr. W.G. Acute cardio respiratory toxicity of miconazole in dogs.  Abstracts of the 21st ICAAC Presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November 6, 1981.

Andrews CP, Weiner MH. Improved diagnosis of invasive aspergillosis by detection of fungal antigen in bronchoalveolar cell pellets and serum.  Clin Res. 1981;(Abstr.)29:844A.

Andrews CP, Smith JD, Johanson Jr. WG. Clinical determinants of persistent abnormalities of diffusing capacity in survivors of adult respiratory distress syndrome. Chest. 1981;(Abstr.)82:214.

Andrews CP, Weiner MH. Aspergillus antigen detection from patients with invasive aspergillosis and aspergillomas.  Am J Med. 1982;73:372-380.

Andrews CP. Chronic obstructive pulmonary disease. In: Holt GR, Mattox DE, Gates GA, authors. Decision making in otolaryngology. Philadelphia: B.C. Decker, Inc; 1984. p. 214-215.

Bell RC, Andrews CP. Pleural effusions: meeting the diagnostic challenge.  Geriatrics. 1985 40(4):101-108.

Campbell GD, Andrews CP, Smith JD, Johanson Jr. WG. The adult respiratory distress syndrome due to nonpulmonary sepsis: Determinants of survival.  Crit Care Med. (Abstr.)10:229.

Bell RC, Andrews CP. Pleural effusions. Respiratory Diseases Digest. 1985, Dec.

Weiner MH, Talbot GH, Gerson SL, Fetchick R, Andrews C, Peacock J, Filice G, Cohen M, Provencher M, Cassileth P. Detection of fungal antigen in body fluids for diagnosis of invasive aspergillosis. Zentralbl Bakteriol Mikrobiol Hyg. 1986; (Abstr.) 261(4):517-522.

Jacobs RL, Andrews CP, Jacobs FO. Hypersensitivity pneumonitis treated with an electrostatic dust filter.  Ann Intern Med. 1989;110:115–118.

Peters JI, Bell RC, Prihoda TJ, Harris G, Andrews CP, Johanson WG. Clinical determinants of abnormalities in pulmonary functions in survivors of the adult respiratory distress syndrome. Am Rev Respir Dis. 1989;139:1163-1168.

Kitziger KJ, Sanders WE, Andrews CP. Acute pulmonary edema associated with use of low-molecular weight dextran for prevention of microvascular thrombosis. J Hand Surg [Am]. 1990;15(6):902-905.

Jacobs RL, Andrews CP, Coalson J. Organic antigen-induced interstitial lung disease: diagnosis and management.  Ann Allergy Asthma Immunol. 2002;88:3041.

Martin BG, Andrews CP, VanBavel JH, Hampel FC, Philpot EE, Baidoo CA, Richard KA. Intranasal fluticasone propianate provided greater relief compared to oral montelukast for nasal congestion and other daytime and evening nasal symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2003;(Abstr.)3(2): S85.

Jacobs RL, Andrews CP. Hypersensitivity pneumonia-nonspecific interstitial pneumonia/fibrosis histopathologic presentation: a study in diagnosis and long-term management.  Ann Allergy Asthma Immunol. 2003;90:265-270.

Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med. 2004;3(5):329-336.

Jacobs RL, Andrews CP, Coalson J. Hypersensitivity pneumonitis: beyond classic occupational disease-changing concepts of diagnosis and management. Ann Allergy Asthma Immunol. 2005;95:115-128.

Donohue JF, Parsey M, Andrews CP. Levalbuterol in the treatment of chronic obstructive pulmonary disease. Chest. 2005;(Abstr.)128:42065.

Weston-Davies WH, Ratner PH, Andrews CP, Pasesen GC, Nuttall PA. High affinity histamine binding protein attenuates nasal allergen challenge induced allergic rhinitis. J Allergy Clin Immunol. 2006; (Abstr.)117(2):S321.

Martin BG, Andrews CP, VanBavel JH, Hampel FC, Klein KC, Prillamaan BA, Faris MA, Philpot EE. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol. 2006; 96:851-857.

Donohue JF, Parsey M, Andrews CP, D’Urzo T, Sharma S, Schafer K, Claus R, Baumgartner RA. Evaluation of the efficacy and safety of levalbuteral in subjects with COPD. COPD. 2006; 3(3):125-132.

Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews CP, Prabhu R, Donohue JF, Watt R, Schlenker-Hercey R, Barnatham ES, Murray J. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am Respir Crit Care Med. 2007;175:926-934.

Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler WT, Wu W, Faris MA, Philpot EE. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 2007;28(2):216-225.

Ratner PH, Andrews CP, Van Bavel J, Toler T, Ellsworth A, Philpot EE. Once-daily fluticasone furoate nasal spray effectively treats ocular symptoms of seasonal allergic rhinitis (SAR) caused by mountain cedar pollen. J Allergy Clin Immunol. 2007;(Abstr.)119(2):S231.

Andrews CP, Martin R, Jacobs RL, Toler WT, Prillaman BA, Philpot EE. Efficacy of fluticosone furoate nasal spray versus oral fexofenadine or nighttime sleep disturbance caused by seasonal allergic rhinitis (SAR) symptoms. (Abstr.) Presented at the American College of Allergy and Immunology, November 12, 2007.

Tashkin DP, Luther M, Andrews CP, Toulinson L, Rinehart M, Denis-Mizek. K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Meds. 2008;102(4):479- 487.

Martin BG, Andrews CP, Mohar DE, Jacobs RL, Toler WT, Prillaman BA, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvements in relieving nighttime nasal symptoms and increasing peak nasal inspiratory flow vs. oral fexofenadine in subjects with seasonal allergic rhinitis. J Allergy Clin Immunol. 2008;(Abstr.)121(2):S54(Supplement). Presented at the American Academy of Allergy Asthma and Immunology, March 15, 2008.

Andrews CP, Martin BG, Jacobs RL, Diaz J, Prillaman BA, Dalal A, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvement in nocturnal quality of life in subjects with seasonal allergic rhinitis compared with oral fexofenadine. J Allergy Clin Immunol. 2008; (Abstr.)121(2):S53 (Supplement). Presented at the American Academy of Allergy Asthma and Immunology, March 15, 2008.

Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz J, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE.  Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009;30(2):128-138.

Meltzer EO, Andrews CP, Journeay G, Lim J, Prillaman BA, Garis C, Philpot EE. Comparison of patient preference for sensory attributes of fluticasonefuroate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol. 2010;104:31-338.

Jacobs RL, Ramirez DA, Andrews CP. Validation of the Biogenics Research Chamber for Juniperus ashei (mountain cedar) pollen. Ann Allergy Asthma Immunol. 2011;107:133-138.

Ramirez DA, Jacobs RL, Andrews CP. Juniperus ashei (mountain cedar) pollen utilized as an antigen in the Biogenics Chamber: comparison of natural and controlled exposures. J Allergy Clin Immunol. 2011 Feb;(Abstr.)127(2):AB19.

Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, Ahuja SK. Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identifies allergic rhinoconjunctivitis endotypes. J Allergy Clin Immunol. 2012;130:122-28.

Ratner PH, Andrews CP, Martin B, Howland W, Desai SY, Haung H, Hinkle J,  Bode F. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen. Allergy Asthma Proc. 2012;33:27-35.

Nayak AS, Andrews CP, Bernstein DI, Dorinsky PM, Tankelevich A, Ding Y, Tantry SK. Long-term (52-Week) treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg once daily) is safe and effective in adult and adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol. 2012;129:AB189.

Ramirez DA, Jacobs RL, Harper NL, He W, Rather CG, Andrews CP, Ahuja SK. High correlation between responses to Mountain Cedar pollen in a pollen challenge chamber vs seasonal exposure. Ann Allergy Asthma Immunol. 2012; (Abstr.)109(5):A28 (Supplement). Presented at the American College of Allergy, Asthma and Immunology Annual Meeting, 2012.

Ramirez DA, Rather CG, Harper NL, Carrillo AR, He W, Andrews CP, Ahuja SK, Jacobs RL. Exposure to Juniperus asheii (Mt. Cedar) and Virginia Live Oak pollen in a pollen exposure chamber elicits similar symptomatology when compared to natural season. J Allergy Clin Immunol. 2013;(Abstr.)131(2):AB49 (Supplement). Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, 2013.

Jacobs RL, He W, Harper NL, Andrews CP, Rather CG, Ramirez DA, Ahuja SK. Heightened exposure to Quercus virginia (Virginia Live Oak) during natural season exposure versus pollen challenge chamber exposure: role of co-factors. J Allergy Clin Immunol. 2013;(Abstr.)131(2):AB76 (Supplement). Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, 2013.

Harper NL, Castiblanco J, Rather CG, Andrews CP, Ramirez DA, Jacobs RL, He W, Ahuja SK. RNA-Seq-Derived whole genome transcriptomic profiling following challenge to Mt. Cedar in a pollen challenge chamber uncover novel insights into allergic rhinoconjunctivitis pathogenesis. J Allergy Clin Immunol. 2013; (Abstr.)131(2):AB40 (Supplement). Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, 2013.

He W, Carrillo AR, Harper NL, Jimenez F, Martinez H, Ahuja SK, Rather CG, Ramirez DA, Andrews CP, Jacobs RL, Ahuja SK. Exposure to Juniperus asheii (Mt. Cedar) pollen in a pollen challenge chamber elicits changes in white blood cell counts and cytokines in mountain cedar positive and negative subjects. J Allergy Clin Immunol. 2013;(Abstr.)131(2):AB45 (Supplement). Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, 2013.

Andrews CP, Ratner PH, Ehler BR, Brooks EG, Pollock BH, Ramirez DA, Jacobs RL. The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2013 July;111(1):9-13.

He W, Harper N, Carrillo A, Andrews CP, Rather CG, Ramirez DA, Jacobs RL, Ahuja SK. Atopic and non-atopic individuals manifest partly concordant clinical and leukocyte responses following exposure to house dust mite in an allergen challenge chamber (ACC). J Allergy Clin Immunol. 2014 Feb; (Abstr.) 133(2):AB223. Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, March, 2014.

Ramirez DA, Jacobs RL, Rather CG, Carrillo A, He W, Harper N, Andrews CP, Ahuja SK. Baseline predictors of symptom severity following exposure to house dust mite in an antigen challenge chamber (ACC). J Allergy Clin Immunol.  2014 Feb;(Abstr.)133(2):AB221. Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, March, 2014.

Jacobs RL, Rather CG, Jimenez F, Martinez H, He W, Ramirez DA, Andrews CP, Ahuja SK. Validation of Biogenics Research Chamber for elicitation of symptoms to dust mite antigen (Der p1). J Allergy Clin Immunol. 2014 Feb; (Abstr.)133(2):AB221. Presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, March 2014.

Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, Ahuja SK. Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. J Allergy Clin Immunol. 2014; 133(5): 1340-1346.

Jacobs RL, Ramirez DA, Rather CG, Andrews CP. Assessing timothy grass pollen sensitivity in South Texas utilizing the Biogenics Research Chamber. 2014 June; (Abstr.). Presented at the European Academy of Allergy and Immunology in Copenhagen, June 2014.

Weinstein SF, Andrews CP, Shah SR, Chylack LT Jr, Tankelevich A, Ding Y, Tantry SK. Long-term efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol. Allergy Asthma Proc. 2014 Jul; 35(4): 323-331.

Jacobs RL, Andrews CP, Ramirez DA, Rather CG, Harper N, Jimenez F, Martinez H, Manoharan M, Carrillo AR, Gerardi M, Esch RE, He W, Ahuja SK. Symptom dynamics during repeated serial allergen chamber exposures to house dust mite [Letter to the Editor]. J Allergy Clin Immunol. 2015 April; 135(4): 1071-1075.

Ramirez DA, Andrews CP, Rather CG, Jacobs RL. Responsiveness to Timothy grass pollen in individuals without known natural exposure in an allergen challenge chamber. Ann Allergy Asthma Immunol. 2015; 114: 226-232.

He W, Jimenez F, Martinez H, Harper NL, Manoharan MS, Carrillo A, Ingale P, Liu Y, Ahuja SS, Clark RA, Rather CG, Ramirez DA, Andrews CP, Jacobs RL, Ahuja SK. Cockroach sensitization mitigates allergic rhinoconjunctivitis symptom severity in patients allergic to house dust mites and pollen. J Allergy Clin Immunol. 2015 Sept; 136(3): 658-666.

Our center specializes in clinical trials for:
  • Abdominal Pain
  • Allergy Medications
  • Allergic Rhinitis
  • Antibiotics
  • Antihistamines
  • Antihypertensives
  • Asthma
  • BCP’s
  • Bronchitis
  • Bronchodilators
  • Constipation
  • COPD
  • Diabetes
  • Diagnosis of Carcinoma
  • Dyslipidemia
  • Dyspepsia
  • HRT
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hypertension
  • Inhaled and Nasal Corticosteroids
  • Insomnia
  • Intravenous sedation
  • Irritable bowel syndrome
  • Metabolic Syndrome
  • Obesity
  • Osteoarthritis
  • Osteoporosis
  • Pollen chamber experience
  • Pulmonary Fibrosis
  • Respiratory Medications
  • Sleep Medications
  • Smoking Cessation
  • Sputum/Cytology
  • Stress Urinary Incontinence Medications
  • Vaccines